{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:10:13Z","timestamp":1788527413559,"version":"build-2803163510"},"reference-count":42,"publisher":"Innovative Healthcare Institute","issue":"2","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Soft tissue sarcomas (STSs) are a group of rare cancers, among which nuclear protein in testis (NUT) sarcomas represent an ultra-rare subset driven by NUTM1 gene fusions. This article presents two unique cases of NUT sarcomas and conducts a comprehensive review of the literature to include an additional 61 cases. Our review reveals that NUT sarcoma exhibits a slightly higher incidence among women (male-to-female ratio of 1:1.03) and tends to manifest at a relatively young age (median age of 40 years). The most prevalent NUT partner genes were the MAD family in 52% of patients (33 of 63 patients, including MGA [n = 12], MXD4 [n = 12], MXD1 [n = 2], and MXI1 [n = 7]), CIC in 30% of patients (n = 19), and bromodomain (BRD) proteins in 8% of patients (n = 5 patients total, including BRD4 [n = 4] and BRD3 [n = 1]). Although 60% of NUT sarcomas (38 of 63 patients) are diagnosed in early stages, half of these patients (19 of 38 patients) experienced relapse despite curative-intent surgery. The median survival of the 21 patients evaluable for survival was 14 months. Finally, among 21 patients who received systemic therapy, only three patients receiving chemotherapy showed disease control, as defined by response or stability of the disease. This article emphasizes the importance of prompt diagnosis through immunohistochemistry and\/or next-generation sequencing testing, advocates for the establishment of a NUT sarcoma registry, and emphasizes the need for clinical trials to advance drug development for this rare disease. Delving into a detailed analysis of pathogenesis of the distinct NUT fusions, this article reviews innovative treatment approaches to NUT sarcoma. These strategies include BRD and extraterminal (BET) inhibitors, trabectedin, inhibitors of the EP300 histone acetyltransferase, and histone deacetylase inhibitors such as vorinostat. In the absence of clinical trials, the results from this review suggest that trabectedin-based or ifosfamide-based regimens, particularly in combination with doxorubicin, may offer a reasonable approach as frontline therapy for NUT sarcomas.<\/jats:p>","DOI":"10.36401\/jipo-24-28","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T02:05:36Z","timestamp":1741140336000},"page":"113-120","source":"Crossref","is-referenced-by-count":3,"title":["Advancing Understanding and Therapeutic Strategies for NUT Sarcomas: Comprehensive Review of the Literature and Two Cases"],"prefix":"10.36401","volume":"8","author":[{"given":"Carlos","family":"Torrado","sequence":"first","affiliation":[{"name":"1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Nassif Haddad","sequence":"additional","affiliation":[{"name":"2 Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta","family":"Somaiah","sequence":"additional","affiliation":[{"name":"2 Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlos","family":"Msaouel","sequence":"additional","affiliation":[{"name":"3 Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Lazar","sequence":"additional","affiliation":[{"name":"4 Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"},{"name":"5 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9455-1660","authenticated-orcid":true,"given":"Sarina A.","family":"Piha-Paul","sequence":"additional","affiliation":[{"name":"1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"2025030507053108800_i2590-017X-8-2-113-b01","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2025030507053108800_i2590-017X-8-2-113-b02","first-page":"99","volume-title":"Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975\u20131995, National Cancer Institute, SEER Program. NIH Pub. No","author":"Ries","year":"1999"},{"key":"2025030507053108800_i2590-017X-8-2-113-b03","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4103\/ortho.IJOrtho_220_17","article-title":"Soft-tissue sarcomas","volume":"52","author":"Vodanovich","year":"2018","journal-title":"Indian J Orthop"},{"key":"2025030507053108800_i2590-017X-8-2-113-b04","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/gcc.22335","article-title":"Gene fusions in soft tissue tumors: recurrent and overlapping pathogenetic themes","volume":"55","author":"Mertens","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"2025030507053108800_i2590-017X-8-2-113-b05","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.3390\/curroncol28060381","article-title":"NUTM1-rearranged neoplasms\u2014a heterogeneous group of primitive tumors with expanding spectrum of histology and molecular alterations\u2014an updated review","volume":"28","author":"Luo","year":"2021","journal-title":"Curr Oncol"},{"key":"2025030507053108800_i2590-017X-8-2-113-b06","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1158\/1078-0432.CCR-12-1153","article-title":"Clinicopathologic features and long-term outcomes of NUT midline carcinoma","volume":"18","author":"Bauer","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2025030507053108800_i2590-017X-8-2-113-b07","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1158\/1078-0432.CCR-22-0591","article-title":"Report of the First International Symposium on NUT Carcinoma","volume":"28","author":"French","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025030507053108800_i2590-017X-8-2-113-b08","doi-asserted-by":"crossref","first-page":"914031","DOI":"10.3389\/fonc.2022.914031","article-title":"NUT carcinoma-an underdiagnosed malignancy","volume":"12","author":"Lauer","year":"2022","journal-title":"Front Oncol"},{"key":"2025030507053108800_i2590-017X-8-2-113-b09","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nrc3659","article-title":"NUT midline carcinoma","volume":"14","author":"French","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"2025030507053108800_i2590-017X-8-2-113-b10","doi-asserted-by":"crossref","first-page":"pkz093","DOI":"10.1093\/jncics\/pkz093","article-title":"Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors","volume":"4","author":"Piha-Paul","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"2025030507053108800_i2590-017X-8-2-113-b11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025030507053108800_i2590-017X-8-2-113-b12","doi-asserted-by":"crossref","first-page":"E244","DOI":"10.1002\/dc.24968","article-title":"Cytomorphology of NUTM1-rearranged sarcoma involving pleural fluid","volume":"50","author":"Chen","year":"2022","journal-title":"Diagn Cytopathol"},{"key":"2025030507053108800_i2590-017X-8-2-113-b13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13000-024-01499-w","article-title":"CIC::NUTM1 sarcomas occurred in soft tissues of upper limbs: a rare case report and literature review","volume":"19","author":"Zhao","year":"2024","journal-title":"Diagn Pathol"},{"key":"2025030507053108800_i2590-017X-8-2-113-b14","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41379-019-0206-z","article-title":"NUTM1-rearranged neoplasia: a multi-institution experience yields novel fusion partners and expands the histologic spectrum","volume":"32","author":"Stevens","year":"2019","journal-title":"Mod Pathol"},{"key":"2025030507053108800_i2590-017X-8-2-113-b15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/gcc.22668","article-title":"Novel MXD4-NUTM1 fusion transcript identified in primary ovarian undifferentiated small round cell sarcoma","volume":"57","author":"Tamura","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"2025030507053108800_i2590-017X-8-2-113-b16","doi-asserted-by":"crossref","first-page":"a003194","DOI":"10.1101\/mcs.a003194","article-title":"A recurrent novel MGA-NUTM1 fusion identifies a new subtype of high-grade spindle cell sarcoma","volume":"4","author":"Diolaiti","year":"2018","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"2025030507053108800_i2590-017X-8-2-113-b17","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1177\/10668969221092125","article-title":"Primary spindle cell sarcoma of the lung with MGA::NUTM1 Fusion: an extremely rare case of a potentially emerging entity and review of the literature","volume":"30","author":"Georgantzoglou","year":"2022","journal-title":"Int J Surg Pathol"},{"key":"2025030507053108800_i2590-017X-8-2-113-b18","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2606)","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann Oncol"},{"key":"2025030507053108800_i2590-017X-8-2-113-b19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting bromodomains: epigenetic readers of lysine acetylation","volume":"13","author":"Filippakopoulos","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"2025030507053108800_i2590-017X-8-2-113-b20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrm.2016.143","article-title":"Functions of bromodomain-containing proteins and their roles in homeostasis and cancer","volume":"18","author":"Fujisawa","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025030507053108800_i2590-017X-8-2-113-b21","doi-asserted-by":"crossref","first-page":"38755","DOI":"10.1074\/jbc.M112.412015","article-title":"Cross-talk among RNA polymerase II kinases modulates C-terminal domain phosphorylation","volume":"287","author":"Devaiah","year":"2012","journal-title":"J Biol Chem"},{"key":"2025030507053108800_i2590-017X-8-2-113-b22","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.3390\/cancers14092234","article-title":"NUT is a driver of p300-mediated histone hyperacetylation: from spermatogenesis to cancer","volume":"14","author":"Rousseaux","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025030507053108800_i2590-017X-8-2-113-b23","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-10-3513","article-title":"Differentiation of NUT midline carcinoma by epigenomic reprogramming","volume":"71","author":"Schwartz","year":"2011","journal-title":"Cancer Res"},{"key":"2025030507053108800_i2590-017X-8-2-113-b24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-pathol-011811-132438","article-title":"Pathogenesis of NUT midline carcinoma","volume":"7","author":"French","year":"2012","journal-title":"Annu Rev Pathol"},{"key":"2025030507053108800_i2590-017X-8-2-113-b25","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1074\/jbc.M114.600759","article-title":"Mechanistic analysis of the role of bromodomain-containing protein 4 (BRD4) in BRD4-NUT oncoprotein-induced transcriptional activation","volume":"290","author":"Wang","year":"2015","journal-title":"J Biol Chem"},{"key":"2025030507053108800_i2590-017X-8-2-113-b26","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.3390\/molecules28073043","article-title":"BET bromodomain inhibitors: novel design strategies and therapeutic applications","volume":"28","author":"To","year":"2023","journal-title":"Molecules"},{"key":"2025030507053108800_i2590-017X-8-2-113-b27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.gene.2011.12.027","article-title":"Regulation of gene transcription by the oncoprotein MYC","volume":"494","author":"Luscher","year":"2012","journal-title":"Gene"},{"key":"2025030507053108800_i2590-017X-8-2-113-b28","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U","article-title":"Repression by the Mad(Mxi1)-Sin3 complex","volume":"20","author":"Schreiber-Agus","year":"1998","journal-title":"Bioessays"},{"key":"2025030507053108800_i2590-017X-8-2-113-b29","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/gcc.22838","article-title":"Emerging entities in NUTM1-rearranged neoplasms","volume":"59","author":"McEvoy","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"2025030507053108800_i2590-017X-8-2-113-b30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41374-020-00484-3","article-title":"A MXI1-NUTM1 fusion protein with MYC-like activity suggests a novel oncogenic mechanism in a subset of NUTM1-rearranged tumors","volume":"101","author":"McEvoy","year":"2021","journal-title":"Lab Invest"},{"key":"2025030507053108800_i2590-017X-8-2-113-b31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/path.5053","article-title":"Transcriptomic definition of molecular subgroups of small round cell sarcomas","volume":"245","author":"Watson","year":"2018","journal-title":"J Pathol"},{"key":"2025030507053108800_i2590-017X-8-2-113-b32","first-page":"342","article-title":"CIC-DUX4 sarcomas","volume":"34","author":"Brahmi","year":"2022","journal-title":"Curr Opin Oncol"},{"key":"2025030507053108800_i2590-017X-8-2-113-b33","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/PAS.0000000000000846","article-title":"Sarcomas with CIC-rearrangements are a distinct pathologic entity with aggressive outcome: a clinicopathologic and molecular study of 115 cases","volume":"41","author":"Antonescu","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"2025030507053108800_i2590-017X-8-2-113-b34","doi-asserted-by":"crossref","first-page":"735","DOI":"10.5858\/arpa.2021-0153-OA","article-title":"CIC-NUTM1 sarcomas affecting the spine","volume":"146","author":"Yang","year":"2022","journal-title":"Arch Pathol Lab Med"},{"key":"2025030507053108800_i2590-017X-8-2-113-b35","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1038\/onc.2013.462","article-title":"Mode of action of trabectedin in myxoid liposarcomas","volume":"33","author":"Di Giandomenico","year":"2014","journal-title":"Oncogene"},{"key":"2025030507053108800_i2590-017X-8-2-113-b36","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/annonc\/mdp004","article-title":"Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series","volume":"20","author":"Grosso","year":"2009","journal-title":"Ann Oncol"},{"key":"2025030507053108800_i2590-017X-8-2-113-b37","doi-asserted-by":"crossref","first-page":"1042479","DOI":"10.3389\/fonc.2022.1042479","article-title":"Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: a proof of principle from a post-hoc analysis","volume":"12","author":"Palmerini","year":"2022","journal-title":"Front Oncol"},{"key":"2025030507053108800_i2590-017X-8-2-113-b38","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(15)70098-7","article-title":"Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study","volume":"16","author":"Kawai","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025030507053108800_i2590-017X-8-2-113-b39","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.ejca.2014.01.012","article-title":"Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas","volume":"50","author":"Blay","year":"2014","journal-title":"Eur J Cancer"},{"key":"2025030507053108800_i2590-017X-8-2-113-b40","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1038\/s41388-020-1301-9","article-title":"Therapeutic targeting of p300\/CBP HAT domain for the treatment of NUT midline carcinoma","volume":"39","author":"Zhang","year":"2020","journal-title":"Oncogene"},{"key":"2025030507053108800_i2590-017X-8-2-113-b41","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/pbc.25350","article-title":"Histone deacetylase inhibitor for NUT midline carcinoma","volume":"62","author":"Maher","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"2025030507053108800_i2590-017X-8-2-113-b42","unstructured":"NUT Carcinoma Registry. Accessed Oct 3, 2024. nc-registry.org"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/8\/2\/113\/3496236\/10.36401_jipo-24-28.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/8\/2\/113\/3496236\/10.36401_jipo-24-28.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:38Z","timestamp":1765475318000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/8\/2\/article-p113.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3,5]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-24-28","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,1]]}}}